Depression drug developer NRX Pharmaceuticals' Q3 loss narrows
NRXP•NRX Pharmaceuticals reported a third-quarter net loss of $2.2 million, or $0.05 per share, narrower than a year earlier, as net patient service revenue rose year over year. Its preservative-free ketamine has FDA approval, and its commercial launch is underway.
1. Quarterly results and launch
NRX Pharmaceuticals said growth at its HOPE Therapeutics clinics lifted third-quarter net patient service revenue year over year. The company posted a net loss of $2.2 million, or $0.05 per share, and said higher selling, general and administrative expenses reflected preparations to launch its FDA-approved preservative-free ketamine. A 17-person sales force is in place, and the company estimates the initial U.S. market for the drug at $400 million, growing 15% annually. It plans to add more sterile injectable products in 2027, aiming to double the market opportunity.




